耀才團隊: 恆指繼續於區間上落
耀才證券研究部團隊稱,隔晚(15日)美股三大指數全線收升逾1%,美國民主共和兩黨就政府財政刺激經濟方案談判有進展,同時生物技術公司Moderna研發的新冠疫苗預料周末成為第二隻開始付運的疫苗,道指重返30,000點。港股有望跟隨外圍先行反彈過百點,MSCI明晟表示將會把10間中資公司的股份,自旗下部分指數中剔除,當中包括中交建(01800.HK)、中車(01766.HK)、中芯(00981.HK)及中鐵建(01186.HK),有關措施將於1月5日收市後開始生效。中芯亦於今早停牌,公告指有美國證券交易場外市場的投資者對公司提出集體訴訟,留意事態發展。清潔護理新股藍月亮(06993.HK)今日(16日)首掛,隔晚於多個暗盤市場表現不一,其中最高見19.4元,較招股價高44.3%,留意今日股價表現。
從技術上看,恆指至今仍處於高位整固階段之悶局。維持較早前的看法,一日恆指仍處於26,000點至27,000點關口,後市仍缺乏明確方向,但一日恆指未失守26,000點關口,目前仍不宜胡亂看淡。
(筆者為證監會持牌人)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.